Drug Profile
Research programme: vascular targeting therapies - VBL Therapeutics
Alternative Names: GT-211Latest Information Update: 11 Mar 2015
Price :
$50
*
At a glance
- Originator Vascular Biogenics
- Developer VBL Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Ischaemia; Peripheral vascular disorders; Wounds
Most Recent Events
- 16 May 2006 Preclinical trials in Age-related macular degeneration in Israel (unspecified route)
- 16 May 2006 Preclinical trials in Ischaemia in Israel (unspecified route)
- 16 May 2006 Preclinical trials in Peripheral vascular disorders in Israel (unspecified route)